Design, synthesis and evaluation of OA-tacrine hybrids as cholinesterase inhibitors with low neurotoxicity and hepatotoxicity against Alzheimer’s disease

References

• Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci. 2017;24 (1):47.
   PubMed Web of Science ®Google Scholar
• Xiao G, Li Y, Qiang X, Xu R, Zheng Y, Cao Z, Luo L, Yang X, Sang Z, Su F, et al. Design, synthesis and biological evaluation of 4'-aminochalcone – rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg Med Chem. 2017;25 (3):1030–1041.
   PubMed Web of Science ®Google Scholar
• Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. 1907;64:146–−148.
   Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2(8000):1403.
   PubMed Web of Science ®Google Scholar
• Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12(10):383–388.
   PubMed Web of Science ®Google Scholar
• Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol. 2010;69(2):155–167.
   PubMed Web of Science ®Google Scholar
• Scarpini E, Schelterns P, Feldman H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol. 2003;2(9):539–547.
   PubMed Web of Science ®Google Scholar
• Bush AI, Tanzi RE. Therapeutics for Alzheimer’s disease based on the metal hypothesis. Neurotherapeutics. 2008;5(3):421–432.
   PubMed Web of Science ®Google Scholar
• Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013;36(4):375–399.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh A., Ekavali A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195–203.
   PubMed Web of Science ®Google Scholar
• Soukup O, Jun D, Zdarova-Karasova J, Patocka J, Musilek K, Korabecny J, Krusek J, Kaniakova M, Sepsova V, Mandikova J, et al. A resurrection of 7-MEOTA: a comparison with tacrine. CAR. 2013;10(8):893–906.
   Google Scholar
• Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994; 271(13):992–998.
   PubMed Web of Science ®Google Scholar
• Gracon SI, Knapp MJ, Berghoff WG, Pierce M, DeJong R, Lobbestael SJ, Symons J, Dombey SL, Luscombe FA, Kraemer D. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord. 1998;12(2):93–101.
   PubMed Web of Science ®Google Scholar
• Pollier J, Goossens A. Oleanolic acid. Phytochemistry. 2012;77:10–15.
   PubMed Web of Science ®Google Scholar
• Ludeña-Huaman MA, Ramos-Inquiltupa DA. Determination of the content of ursolic and oleanolic acid in the cuticular wax of fruits of different species of rosaceae. Rev Colomb Quim. 2019;48(2):15–20.
   Web of Science ®Google Scholar
• Zhao H, Zhou M, Duan L, Wang W, Zhang J, Wang D, Liang X. Efficient synthesis and anti-fungal activity of oleanolic acid oxime esters. Molecules. 2013;18(3):3615–3629.
   PubMed Web of Science ®Google Scholar
• Hoskeri HJ, Krishna V, Kumar BV, Shridar AH, Babu KR, Sudarshana MS. In vivo prophylactic effects of oleanolic acid isolated from chloroform extract of Flaveria trinervia against ethanol induced liver toxicity in rats. Arch Pharm Res. 2012;35(10):1803–1810.
   PubMed Web of Science ®Google Scholar
• Ullian ME, Hazen-Martin DJ, Walsh LG, Davda RK, Egan BM. Carbenoxolone damages endothelium and enhances vasoconstrictor action in aortic rings. Hypertension. 1996;27(6):1346–1352.
   PubMed Web of Science ®Google Scholar
• Liu J. Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol. 2005;100(1-2):92–94.
   PubMed Web of Science ®Google Scholar
• Çulhaoğlu B, Yapar G, Dirmenci T, Topçu G. Bioactive constituents of Salvia chrysophylla Stapf. Nat Prod Res. 2013;27(4-5):438–447.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee KT, Yang JH, Baek NI, Kim DK. Acetylcholinesterase inhibitors from the twigs of Vaccinium oldhami Miquel. Arch Pharm Res. 2004;27(1):53–56.
   PubMed Web of Science ®Google Scholar
• Loesche A, Köwitsch A, Lucas SD, Al-Halabi Z, Sippl W, Al-Harrasi A, Csuk R. Ursolic and oleanolic acid derivatives with cholinesterase inhibiting potential. Bioorg Chem. 2019;85:23–32.
   PubMed Web of Science ®Google Scholar
• Li HN, Liu Y, Zhang ZP, Wang ZP, Hao JZ, Li FR, Fan ZF, Zou LB, Cheng MS. Synthesis, biological evaluation and structure-activity relationship studies of hederacolchiside E and its derivatives as potential anti-Alzheimer agents. Eur J Med Chem. 2018;143:376–389.
   PubMed Web of Science ®Google Scholar
• Cai P, Fang SQ, Yang HL, Yang XL, Liu QH, Kong LY, Wang XB. Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer’s disease agents with cholinergic, antioxidant, and neuroprotective properties. Eur J Med Chem. 2018;157:161–176.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7(2):88–95.
   PubMed Web of Science ®Google Scholar
• León R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget- directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev. 2013;33(1):139–189.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun J, Fang L, Liu M, Peng S, Liao H, Lehmann J, Zhang Y. Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J Med Chem. 2012;55(9):4309–4321.
   PubMed Web of Science ®Google Scholar